IntraOp Medical Corporation Announces Purchase of First Mobetron in Southeast Asia by Siriraj Hospital in Thailand

SUNNYVALE, Calif.--(BUSINESS WIRE)-- IntraOp Medical Corporation (OTC:IOPD.PK) today announced that the Faculty of Medicine Siriraj Hospital of Mahidol University (“Siriraj Hospital”) became the first hospital in Southeast Asia to purchase a Mobetron for Intra-Operative Electron Radiation Therapy (IOERT).

Siriraj Hospital is the oldest public hospital in Thailand, founded more than 120 years ago. With 2,600 beds, Siriraj is also one of the largest and most prestigious cancer centers in all of Southeast Asia, treating more than 8,300 new cancer patients per year. Among its many specialty programs, Siriraj has one of Asia’s largest Breast Centers of Excellence. The Breast Center of Excellence provides the women of Thailand and Southeast Asia with programs for breast education and the latest imaging and screening technology for breast cancer. The center treats more than 1,100 breast cancers per year. “We plan to use the Mobetron to benefit our breast cancer patients”, says Dr. Adune Rattanawichitrasin, the Chief of breast surgery. “The data is now clearly emerging that IOERT for breast cancer treatment can result in reduced local recurrence and shorter treatment times. As a Breast Center of Excellence, we feel it was important to add this innovative technology to our program”. In addition, the Mobetron will also be used for advanced and recurrent cancers, such as recurrent head and neck cancer, pancreatic cancer, recurrent rectal cancer, extremity and retroperitoneal sarcomas, and pediatric cancers.

IntraOp’s Mobetron is a mobile, self-shielded, technology that delivers radiation directly to a tumor site during cancer surgery without having to pass through the surrounding body structures. This procedure is called IOERT. The Mobetron enables radiation and surgical professionals to visually pinpoint the optimal site for radiation by seeing the exposed tumor bed and delivering a concentrated beam of radiation to a specific depth during cancer surgery. Clinical studies involving a number of cancer indications such as head and neck, sarcomas, colorectal, pancreatic, and breast, have shown that patients treated with IOERT often have fewer recurrences, which correlates to increased survival.

“We are very pleased to have one of the most prominent hospitals in Southeast Asia join the Mobetron family”, says John Powers, CEO of IntraOp Medical. “We are looking forward to working with the professionals at Siriraj to integrate IOERT into their cancer program and especially to enable them to provide the latest IOERT breast treatment protocols for their renowned Breast Center of Excellence.”

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer intra-operative radiation therapy safely and effectively – for all cancer patients. The company’s flagship product, Mobetron, is the first fully portable, self-shielded intra-operative electron radiation therapy device designed for use in any operating room or office setting. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.


IntraOp Medical Corporation
John Powers, 408-636-1020 ext. 128

KEYWORDS:   United States  Asia Pacific  North America  California  Thailand

INDUSTRY KEYWORDS:   Surgery  Health  Hospitals  Oncology  Radiology